Argus
•
Oct 28, 2026
PTGX: Raising target price to $148.00
Summary
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Bristol-Myers Squibb Company
Oct 30, 2026
•
BMY
Analyst Report: BridgeBio Pharma, Inc.
Oct 28, 2026
•
BBIO
XNCR: Rating increased to a HOLD
Oct 28, 2026
•
XNCR
KRYS: Lowering target price to $353.00
Oct 28, 2026
•
KRYS
RCUS: Lowering target price to $17.00
Oct 28, 2026
•
RCUS
